EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?

Graeme B Bolger iD

International Journal of Molecular Sciences · 11.12.2023 · 24 (24) · 17363

DOI: 10.3390/ijms242417363 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.12.2023. Verfasst von Graeme B Bolger. Beteiligte Einrichtung: BZI Pharma LLC, 1500 1st Ave N., Unit 36, Birmingham, AL 35203-1872, USA. Hauptthemen laut MEDLINE: Precision Medicine, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BZI Pharma LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of a wider range of therapeutic options is a key objective in drug discovery for chronic obstructive pulmonary disease (COPD). Fundamental advances in lung biology have the potential to greatly expand the number of therapeutic targets in COPD. The recently reported successful Phase 3 clinical trial of the first biologic agent for COPD, the monoclonal antibody dupilumab, adds additional support to the importance of targeting inflammatory pathways in COPD. However, numerous other cellular mechanisms are important targets in COPD therapeutics, including airway remodeling, the CFTR ion channel, and mucociliary function. Some of these emerging targets can be exploited by the expanded use of existing COPD drugs, such as roflumilast, while targeting others will require the development of novel molecular entities. The identification of additional therapeutic targets and agents has the potential to greatly expand the value of using clinical and biomarker data to classify COPD into specific subsets, each of which can be predictive of an enhanced response to specific subset(s) of targeted therapies. The author reviews established and emerging drug targets in COPD and uses this as a framework to define a novel classification of COPD based on therapeutic targets. This novel classification has the potential to enhance precision medicine in COPD patient care and to accelerate clinical trials and pre-clinical drug discovery efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicinePulmonary Disease, Chronic ObstructiveHumansLungInflammationAminopyridinesCyclopropanesIon Channels

Stichwörter der Autor:innen

CFTRCREBPKAcAMPensifentrinephosphodiesteraseroflumilast

Substanzen

AminopyridinesCyclopropanesIon Channels

Autor:innen und Institutionen

  • BZI Pharma LLC, 1500 1st Ave N., Unit 36, Birmingham, AL 35203-1872, USA.

ORCID-Profile: Graeme B Bolger

Förderung

  • BZI Pharma LLC

Zitieren

APA

Bolger, G. B. (2023). Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?. International Journal of Molecular Sciences, 24(24), 17363. https://doi.org/10.3390/ijms242417363

Vancouver

Bolger GB. Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?. International Journal of Molecular Sciences. 2023;24(24):17363. doi:10.3390/ijms242417363

BibTeX
@article{Bolger2023,
  author = {Bolger, Graeme B},
  title = {Therapeutic Targets and Precision Medicine in COPD: Inflammation, Ion Channels, Both, or Neither?},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {24},
  pages = {17363},
  doi = {10.3390/ijms242417363}
}
Kostenlos starten →